IOVA · Intrinsic value
Is Iovance Biotherapeutics, Inc. (IOVA) overvalued or undervalued?
As of Oct 20, 2026, TickerWorth publishes a fair-value range of $4.42 – $4.42 for Iovance Biotherapeutics, Inc. (IOVA), against the delayed market price of $14.86: priced above our range. It is a range, not a single number, so we do not call it over- or undervalued. It is a model estimate, and every input behind it is sourced below.
Model by Miraaj Patel · generated from market data · Updated Oct 20, 2026 · How these pages are made
What is IOVA worth?
- Fair-value range
- $4.42 – $4.42
- Market price
- $14.86
- Gap to fair value
- —
- Verdict
- Priced above our range
Reverse DCF, on our cash-flow model rather than the range above: Today's price implies revenue growth of more than 25%/yr. Above about 25% a year the reverse-DCF stops being informative. It solves for revenue growth alone — holding margins, capital intensity and the forecast horizon fixed — so a price well above our cash-flow model's value has nowhere to go but growth, and the solver returns a rate the model can't reconcile. Read it as "the price implies growth we can't justify", not as a forecast.
What is IOVA's TickerWorth Score?
Priced richly vs peers — the business scores well
Compared with Healthcare companies in US
Its strongest point: growing quickly. Its weakest: looks expensive on the numbers.
- Value · 16 of 100
Cheaper than 16% of Healthcare companies in US
- Price vs worth · 0 of 100
- Quality · 19 of 100
More profitable than 19% of Healthcare companies in US
- Financial health · 80 of 100
Financially stronger than 80% of Healthcare companies in US
- Growth · 91 of 100
Growing faster than 91% of Healthcare companies in US
- Momentum · 97 of 100
Outperformed 97% of Healthcare companies in US over the past year
Confidence: Medium confidence · Scored
Get the Undervalued Company of the Week.
Why IOVA gets a range, not one number
At a recent price of $14.86, Iovance Biotherapeutics, Inc. (IOVA) sits above every lens we ran: our valuation lenses put the business somewhere between $4.42 and $4.42 per share. They disagree too widely for us to state a single fair value. We publish the range rather than a midpoint because a number that precise would claim more than the methods can support. This is an educational model, not a price target or a recommendation.
Read the full reasoning
The valuation discounts Iovance Biotherapeutics, Inc.'s projected free cash flows at a weighted-average cost of capital (WACC) of 9.2%, with a long-run terminal growth rate of 2.5%. About 76% of the enterprise value comes from the terminal value — the portion beyond the explicit forecast window — which is typical for a stable, cash-generative business and a reminder that small changes in the discount rate or terminal growth assumption swing the intrinsic value meaningfully.
Running the DCF in reverse — solving for the growth the current price already assumes — IOVA would need sustained revenue growth of more than 25%/yr to justify today's price, against about 16.6% a year compounded in our base case. We don't quote a precise figure here, because past about 25% a year the reverse-DCF stops being informative: it solves for revenue growth alone, holding margins, capital intensity and the forecast horizon fixed, so a price well above our fair value has nowhere to go but growth. The honest reading is that the price implies growth this model can't reconcile — not that we forecast it.
Sensitivity matters more than any single number. Across a reasonable band of discount-rate assumptions, IOVA's modeled DCF value ranges from about $0.79 to $1.06 per share. If that range still sits below today's price, the market is optimistic relative to the model across the whole band; if it brackets the price, the stock is roughly fairly valued on our assumptions. Use the interactive slider to see exactly where your own cost-of-capital view lands.
How to read this page: the DCF fair value is what Iovance Biotherapeutics, Inc. would be worth if its cash flows grow as modeled and are discounted at the stated WACC. The assumptions table shows every input and its source; the reverse-DCF shows what the market believes; the sensitivity band shows how fragile the answer is. None of this is investment advice — it is a transparent, auditable framework for forming your own view of IOVA's intrinsic value. Figures update as new filings and prices come in.
Every input behind IOVA's DCF
| Input | Value |
|---|---|
| Base-year revenueLive feed — totalRevenue (TTM) | $324,970,000 |
| Base EBIT marginComputed — trailing operatingMargins, held roughly flat | 2.0% |
| Forecast revenue growthESTIMATEAssumption — TickerWorth's 5-year explicit forecast | 30% → 24% → 17% → 10% → 4% |
| Risk-free rateLive feed — US 10-year Treasury yield (^TNX) | 5.3% |
| BetaLive feed — yfinance, 5-year monthly beta vs the S&P 500 (clamped to 0.4–2.5) | 0.83 |
| Terminal growthESTIMATEAssumption — TickerWorth house default 2.5%, held below WACC | 2.5% |
| Diluted sharesLive feed — sharesOutstanding | 453M |
| Market priceDelayed quote · as of 2026-10-20 20:18 UTC | $14.86 |
Change IOVA's assumptions
The discount-rate dial and the editable model
ProChange growth, margin and WACC yourself — Pro (7-day free trial, card required).
What does Iovance Biotherapeutics, Inc. do?
What does it do?
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It operates in the Biotechnology industry (Healthcare sector), headquartered in United States. The company employs roughly 975 people.
How does it make money?
The business turns $264M in annual revenue into profit. Out of every $100 of sales, about $0 is left as operating profit (operating margin of -52.3%), after a 48% gross margin on the products/services it sells. After all costs, taxes and interest, -89.1% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks solid: carries modest debt (0.1× equity), comfortably covers its short-term bills (4.3× current ratio), and is currently lossmaking.
Who at IOVA filed insider trades?
| Date | Insider | Relationship | What happened | Value | Filing |
|---|---|---|---|---|---|
| Vogt Frederick G | Director, Interim CEO & General Counsel | Option exercise | — | Form 4 for Vogt Frederick G (opens sec.gov in a new tab) | |
| Vogt Frederick G | Director, Interim CEO & General Counsel | Shares withheld (tax) | $57,750.60 | Form 4 for Vogt Frederick G (opens sec.gov in a new tab) | |
| BILINSKY IGOR | Chief Operating Officer | Option exercise | — | Form 4 for BILINSKY IGOR (opens sec.gov in a new tab) | |
| BILINSKY IGOR | Chief Operating Officer | Shares withheld (tax) | $34,591.20 | Form 4 for BILINSKY IGOR (opens sec.gov in a new tab) | |
| Puri Raj K. | Chief Regulatory Officer | Option exercise | — | Form 4 for Puri Raj K. (opens sec.gov in a new tab) | |
| Puri Raj K. | Chief Regulatory Officer | Shares withheld (tax) | $38,958.60 | Form 4 for Puri Raj K. (opens sec.gov in a new tab) |
A disclosure, not a signal to trade. Source: SEC EDGAR (Form 4). Older filings and the 90-day buying-and-selling read are part of Pro. See plans
Common questions
What is IOVA's intrinsic value?
TickerWorth's valuation lenses put Iovance Biotherapeutics, Inc. (IOVA) between $4.42 and $4.42 per share, versus a market price of $14.86. They disagree too widely for us to state a single fair value, so we publish the range.
Is IOVA overvalued or undervalued?
At $14.86 the price sits above every lens we ran. We don't call IOVA overvalued or undervalued from a range this wide. This is an educational estimate, not advice.
What discount rate is used for IOVA?
A WACC of 9.2% and a terminal growth rate of 2.5%.
Is Iovance Biotherapeutics stock undervalued?
TickerWorth's fair-value range for Iovance Biotherapeutics, Inc. (IOVA) is $4.42 – $4.42 against a market price of $14.86. Priced above our range. We publish a range here, not one number, so we do not call it over- or undervalued. This is a model estimate, not investment advice.
Iovance Biotherapeutics (IOVA) DCF valuation and fair value
Our fair-value range for Iovance Biotherapeutics, Inc. (IOVA) is $4.42 – $4.42, built on a 9.2% discount rate (WACC) and 2.5% terminal growth. It blends our discounted-cash-flow model with other valuation lenses. Every assumption is listed on this page with its source.
What growth is priced into Iovance Biotherapeutics stock?
Today's price implies revenue growth of more than 25%/yr. Above about 25% a year the reverse-DCF stops being informative. It solves for revenue growth alone — holding margins, capital intensity and the forecast horizon fixed — so a price well above our cash-flow model's value has nowhere to go but growth, and the solver returns a rate the model can't reconcile. Read it as "the price implies growth we can't justify", not as a forecast. This is a reverse DCF: it holds our cash-flow model's other inputs and solves for the revenue growth that makes the model equal today's price of $14.86. A model estimate, not investment advice.
Iovance Biotherapeutics (IOVA) insider trading
The most recent insider filing (SEC Form 4) for Iovance Biotherapeutics, Inc. (IOVA): Vogt Frederick G, Director, Interim CEO & General Counsel, option exercise on 2026-09-08. The latest filings are listed on this page. A disclosure, not a signal to trade.
Other ways into the coverage
Not investment advice. TickerWorth Score is a model output.
Educational tool. Every output reflects the assumptions shown — not a prediction and not investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public filings and market data that can be wrong.